Edition:
United Kingdom

Bioverativ Inc (BIVV.OQ)

BIVV.OQ on NASDAQ Stock Exchange Global Select Market

103.79USD
22 Jan 2018
Change (% chg)

-- (--)
Prev Close
$103.79
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
441,912
52-wk High
$104.30
52-wk Low
$41.21

Chart for

About

Bioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein],... (more)

Overall

Beta: --
Market Cap(Mil.): $6,375.17
Shares Outstanding(Mil.): 108.18
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 85.70 16.62
EPS (TTM): -- -- --
ROI: -- 3.19 10.61
ROE: -- 4.52 14.21

Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion

PARIS French healthcare group Sanofi has agreed to buy U.S. haemophilia specialist Bioverativ for $11.6 billion(8.34 billion pounds), its biggest deal for seven years and a major play to strengthen its presence in treatments for rare diseases. | Video

22 Jan 2018

Biotech M&A takes off as Sanofi and Celgene spend $20 billion

Biotech deal activity exploded on Monday with French drugmaker Sanofi and U.S.-based Celgene spending a combined total of more than $20 billion (14.39 billion pounds) to add new products for haemophilia and cancer to their medicine cabinets. | Video

22 Jan 2018

Sanofi digs deep to buy U.S. hemophilia group Bioverativ for $11.6 billion

PARIS French healthcare group Sanofi has agreed to buy U.S. hemophilia specialist Bioverativ for $11.6 billion, its biggest deal for seven years and a major play to strengthen its presence in treatments for rare diseases. | Video

22 Jan 2018

UPDATE 5-Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 bln

* Shares in Sanofi down 4 percent (Updates shares, adds links to Breakingviews and other stories)

22 Jan 2018

BRIEF-Sanofi CFO sees commercial, cost and tax synergies following Bioverativ deal

Jan 22 Sanofi Chief financial officer Jerome Contamine says :

22 Jan 2018

BRIEF-Bioverativ Says Regarding Termination Of Merger Deal With Sanofi Under Certain Circumstances Co Will Be Required To Pay Fee Of $326 Mln

* BIOVERATIV SAYS REGARDING TERMINATION OF MERGER DEAL WITH SANOFI UNDER CERTAIN CIRCUMSTANCES CO WILL BE REQUIRED TO PAY FEE OF $326 MILLION - SEC FILING Source text: (http://bit.ly/2DC3sg7) Further company coverage:

22 Jan 2018

Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion

PARIS French healthcare group Sanofi has agreed to buy U.S. haemophilia specialist Bioverativ for $11.6 billion, its biggest deal for seven years, which it said would strengthen its presence in treatments for rare diseases. | Video

22 Jan 2018

New drugs recast $10 bln haemophilia market as Sanofi swoops in

LONDON, Jan 22 Sanofi is placing a big bet on the $10 billion-a-year haemophilia market at a testing time, as scientific advances overhaul traditional approaches to treating the rare uncontrolled bleeding disorder.

22 Jan 2018

Sanofi shares fall on $11.6 billion Bioverativ takeover

PARIS Shares in French drugmaker Sanofi fell on Monday after the company announced a $11.6 billion takeover of U.S. haemophilia treatment specialist Bioverativ, with some traders saying the price looked expensive.

22 Jan 2018

Sanofi shares fall on $11.6 bln Bioverativ takeover

PARIS, Jan 22 Shares in French drugmaker Sanofi fell on Monday after the company announced a $11.6 billion takeover of U.S. haemophilia treatment specialist Bioverativ, with some traders saying the price looked expensive.

22 Jan 2018

Earnings vs. Estimates